However, further study, especially on the precise mechanism regarding the role of FAM83H-SCRIB in conventional anti-cancer therapies, is needed to select a population of patients who could potentially benefit from anti-FAM83H/SCRIB-targeted therapy. Here, SACK1H is linked to cancer.